Figure 4.
OS for patients with 1 TP53 mutation with VAF ≤40% who received a cytarabine (Ara-C)-based regimen.

OS for patients with 1 TP53 mutation with VAF ≤40% who received a cytarabine (Ara-C)-based regimen.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal